Takeda Pharmaceutical Company

Takeda Pharmaceutical Company is a global pharmaceutical firm that has become a significant counterparty in China's outbound drug-licensing wave. Per a 峰瑞资本 year-end piece, Takeda was part of a milestone transaction with 信达生物 in October 2025 that helped push China's total innovative-drug outbound licensing value past $100 billion for the year . In earlier deals, Takeda has also been on the selling side of assets in China: 海森生物—a joint venture set up in late 2021 by 康桥资本, 合肥产投集团, and 肥东县政府—acquired part of Takeda's prescription-drug business in mainland China in 2022 and formally took over its pipeline, with sales growing 47% in the quarters following . Separately, 康桥资本's control-buyout team led by 付伟 acquired five of Takeda's cardiovascular and metabolic drugs in 2022, a deal he described as widely examined but ultimately executed through operational value creation rather than trend prediction .